Sofinnova Investments

Jakob Dupont, MD MA serves as Executive Partner for Sofinnova Investments. Dr. Dupont brings more than two decades of experience in the field of oncology and other therapeutic areas, in developing therapies and programs dedicated to addressing high unmet medical needs.

Previously, Dr. Dupont also served as Head of Research & Development (R&D) at Atara Biotherapeutics where he led the development of EBVallo^®. He also served as Chief Medical Officer at Gossamer Bio, as well as Global Head of Breast and Gynecologic Cancer Development for Genentech/Roche, where he was responsible for the global development of Herceptin^®, Perjeta^®, Kadcyla^®, Tecentriq^®, among others, and he also previously led the development of Avastin^® for Gynecologic and Breast Cancers. Additionally, he served as Chief Medical Officer of OncoMed Pharmaceuticals. Through his career he has contributed to 14 regulatory approvals, and 22 successful IND filings. Dr. Dupont has served on the Boards or SABs of several companies, including Pyxis Oncology, Ambrx, and Imugene. Dr. Dupont has helped 4 biotechnology companies to go public. In his early career he has maintained academic practices at Memorial Sloan Kettering Cancer Center and Stanford Medical Center.

Dr. Dupont received his M.D. from the Joan & Sanford I. Weill Medical College of Cornell University and his M.A. in philosophy from New York University. He also served as Assistant Chief Resident and completed his Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center (MSK), his Internal Medicine Residency at the New-York Presbyterian Hospital — Cornell Campus, and his Internal Medicine Internship at The University of Michigan Medical Center.